Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death - Takeaways - MDSpire

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

High-risk localized and locally advanced prostate cancer patients treated with apalutamide — a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) — plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, medical oncologist at Dana-Farber Cancer Institute, and Adam Kibel, MD, chair of the Department of Urology at Mass General Brigham.

  • By

  • June 1, 2026

  • 4 min

Share

  • 1

    Apalutamide combined with hormone therapy before and after surgery significantly reduces metastasis and death risk in high-risk prostate cancer patients.

  • 2

    The PROTEUS trial involved 2109 patients and demonstrated improved pathologic responses with apalutamide compared to hormone therapy alone.

  • 3

    Patients receiving apalutamide had a 20% lower risk of metastasis or death and a five-year metastasis-free survival rate of 78.2%.

  • 4

    The study showed that apalutamide treatment delayed subsequent therapy by 33 months, indicating improved disease management.

  • 5

    These findings may reshape the standard of care for high-risk localized or locally advanced prostate cancer patients.

Original Source(s)

Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death

  • by

  • June 1, 2026

Related Content

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Case Report: A rare triad of neoplasms: navigating synchronous accessory breast cancer, papillary thyroid carcinoma, and inflammatory nasal papilloma